A new polymer is investigated as a drug-delivery vehicle for the treatment of inflammatory diseases, such as cardiac dysfunction. The biocompatibility, neutral degradation products and controlled-release properties of the polyketal microparticles indicate the material’s promising future in inflammation inhibition.
- Jay C. Sy
- Gokulakrishnan Seshadri
- Michael E. Davis
